Brokerages Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Price Target at $28.98

Posted by Francis Steltz on Aug 29th, 2026

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) has been given an average rating of “Hold” by the twenty-three research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $28.9750.

A number of brokerages recently weighed in on TNDM. Barclays set a $55.00 price objective on Tandem Diabetes Care and gave the company an “overweight” rating in a research note on Monday, May 11th. Citigroup reiterated a “neutral” rating and set a $21.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, August 7th. Weiss Ratings cut shares of Tandem Diabetes Care from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. William Blair initiated coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They set an “outperform” rating for the company. Finally, UBS Group started coverage on shares of Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 target price on the stock.

Check Out Our Latest Analysis on TNDM

Tandem Diabetes Care Stock Up 0.1%

Tandem Diabetes Care stock opened at $21.43 on Monday. Tandem Diabetes Care has a twelve month low of $11.46 and a twelve month high of $29.65. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18. The firm has a market cap of $1.49 billion, a PE ratio of -23.04 and a beta of 1.54. The firm’s 50 day moving average price is $18.56 and its two-hundred day moving average price is $19.17.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.01. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business had revenue of $254.56 million for the quarter, compared to analysts’ expectations of $254.99 million. During the same period in the previous year, the company posted ($0.78) EPS. Tandem Diabetes Care’s revenue was up 5.8% on a year-over-year basis. On average, research analysts predict that Tandem Diabetes Care will post -0.65 EPS for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

A number of hedge funds have recently modified their holdings of TNDM. Vanguard Group Inc. raised its position in Tandem Diabetes Care by 3.9% in the fourth quarter. Vanguard Group Inc. now owns 7,341,356 shares of the medical device company’s stock worth $161,363,000 after purchasing an additional 278,042 shares in the last quarter. Jennison Associates LLC boosted its holdings in Tandem Diabetes Care by 42.3% during the fourth quarter. Jennison Associates LLC now owns 2,021,376 shares of the medical device company’s stock valued at $44,430,000 after purchasing an additional 601,260 shares in the last quarter. First Light Asset Management LLC grew its stake in shares of Tandem Diabetes Care by 20.7% in the 1st quarter. First Light Asset Management LLC now owns 1,314,715 shares of the medical device company’s stock valued at $25,203,000 after purchasing an additional 225,222 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Tandem Diabetes Care by 42.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 193,556 shares of the medical device company’s stock valued at $3,710,000 after purchasing an additional 57,803 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Tandem Diabetes Care in the 1st quarter worth approximately $1,116,000.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.